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CC BY license.Objective: We sought to evaluate the antiviral immune response
in patients with WASP deficiency in vivo.
Methods: Viral clearance and associated immunopathology
were measured after infection of WASP-deficient (WAS KO)
mice with lymphocytic choriomeningitis virus (LCMV).
Induction of antiviral CD81 T-cell immunity and cytotoxicity
was documented in WAS KO mice by means of temporal
enumeration of total and antigen-specific T-cell numbers. Type I
interferon (IFN-I) production was measured in serum in
response to LCMV challenge and characterized in vivo by using
IFN-I reporter mice crossed with WAS KO mice.
Results: WAS KO mice showed reduced viral clearance and
enhanced immunopathology during LCMV infection. This was
attributed to both an intrinsic CD81 T-cell defect and defective
priming of CD81 T cells by dendritic cells (DCs). IFN-I
production byWASKODCswas reduced both in vivo and in vitro.
Conclusions: These studies use a well-characterized model of
persistence-prone viral infection to reveal a critical deficiency of
CD81 T-cell responses in murine WASP deficiency, in which
abrogated production of IFN-I by DCs might play an important
contributory role. These findings might help us to understand
the immunodeficiency of WAS. (J Allergy Clin Immunol
2013;131:815-24.)
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Wiskott-Aldrich syndrome (WAS) is a rare X-linked genetic
human disease associated with thrombocytopenia, eczema, and
life-threatening immunodeficiency.1,2 Patients often also have an
increased incidence of autoimmune disease and malignancies.3,4
WAS is caused by mutations in the gene encoding the Wiskott-
Aldrich syndrome protein (WASP), which is amember of a family
of proteins that are required for the transduction of signals from
the cell surface to the actin cytoskeleton.5 Because expression
ofWASP is restricted to cells of the hematopoietic lineage, the ab-
sence ofWASP results in defective function of many immune cell
lineages, leading to a combined cellular and humoral immune
defect. Defective immune cell function resulting from WASP
deficiency is multifactorial, including global defects of migration
of lymphoid and myeloid lineages,6-10 as well as impaired
cell-specific effector function. For instance, in the absence of
WASP function, uptake of particulate antigen by macrophages815
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816 LANG ET ALby means of phagocytosis is defective,6-12 podosome formation
and T-cell priming ability of dendritic cells (DCs) is im-
paired,6,13-15 B- and T-cell proliferation in response to B- or
T-cell receptor ligation is reduced,16-20 and homeostasis of mature
B-cell populations,21,22 as well as homeostasis and function of
regulatory T cells, is disturbed.23-26 Therefore the severe immu-
nodeficiency resulting from WASP deficiency is thought to be
the result of a complex combination of cellular immune defects.
Although many studies have focused on characterizing the role
of WASP in individual immune cell lineages, much is unknown
about the role ofWASP for antiviral immunity despite a significant
proportion of patients withWAS having recurrent infections, most
commonly involving members of the herpes virus family.3,4 Previ-
ous reports have indicated susceptibility of WAS KO mouse
models to influenza infection, which seemed more pronounced
after secondary viral challenge, reflecting impaired memory func-
tion.27,28 Recently, WASP-deficient CD81 cells derived from pa-
tients have been shown to polarize lytic granules poorly and to
exhibit diminished cytotoxicity.29 Acute and chronic infection
with persistence-prone viruses often results in organ-specific im-
munopathology.30-32 In this setting virus-specific T cells are a ma-
jor determinant of immunopathology because they contribute to
organ infiltration and are directly cytotoxic to virus-infected target
cells.33Mechanismsof virus control and virus-induced immunopa-
thology have been studied inmice by using the noncytopathicRNA
virus lymphocytic choriomeningitis virus (LCMV), in which im-
munopathology is predominantlymediated by CD81T cell–medi-
ated cytotoxicity against virus-infected cells. Complete lack of
CD81 T cells strongly reduces immunopathology, even though
viral replication is enhanced.34 In contrast, delayed innate or adap-
tive immune response also enhances viral replication in the target
organ, leading to exaggerated immunopathology.33,35 In addition
to CD81 T cells, type I interferon (IFN-I) is crucial for the control
of viral replication36 and induced at early time points after viral in-
fection. Host production of IFN-I is elicited by the ligation of host
pattern-recognition receptors by viralmolecules, generally activat-
ing the transcription factor interferon regulatory factor 7, which
then translocates to the nucleus and promotes IFN-I production.37
Herewehave usedmodelsof virus-induced immunopathology to
analyze antiviral immunity in patients with WASP deficiency. We
found thatWASP deficiency results in impaired viral clearance andenhanced immunopathology. This was associated with an impaired
CD81 T-cell response and reduced production of IFN-Is by DCs.METHODS
Mice and viruses
WAS KO, RIP-GP, and IFNbmob/mob mice were bred in our own facilities.
Control C57BL/6 mice were purchased from Charles River (Margate,
United Kingdom). For some experiments, WAS KO mice were crossed with
IFNbmob/mob mice (both on a C57BL/6 background). WAS KO mice were
also crossed to RIP-GP mice (on a C57BL/6 background). For generation of
WAS KO bone marrow chimeras in RIP-GP mice (both on a C57BL/6 back-
ground), recipient mice were irradiated with 1050 rad on day 21. On day 0,
107 bone marrow cells were transferred intravenously, and mice were used
for experiments 7 weeks later. All experiments were performed in single ven-
tilated cages. Animal experiments were carried out either with authorization
of the Veterin€aramt of the Kanton Zurich and in accordance with the Swiss
law for animal protection or with the approval of and according to United
Kingdom Home Office Animal Welfare legislation. Further animal experi-
ments were carried out with the authorization of the Landesamt f€ur Natur,
Umwelt und Verbraucherschutz of Nordrhein-Westfalen, Germany, and in
accordancewith the German law for animal protection, the institutional guide-
lines of the Ontario Cancer Institute, or both.
LCMV strain WE was originally obtained from F. Lehmann-Grube
(Heinrich Pette Institute, Hamburg, Germany) and propagated in L929 cells.
Viral titers were measured by using a plaque-forming assay, as previously
described.38 Mice were infected with 200 plaque-forming units (pfu) of
LCMV-WE unless stated otherwise. Vesicular stomatitis virus (VSV), Indiana
strain (VSV-IND, Mudd-Summers isolate), was originally obtained from
Professor D. Kolakofsky (University of Geneva, Geneva, Switzerland). Virus
was propagated on BHK-21 cells at a multiplicity of infection of 0.01 followed
by plaquing onto Vero cells.Immunohistochemistry
Cryostat sections of 7 mm in thickness were cut onto poly-L-lysine–coated
slides (VWR, Leuven, Belgium), fixed for 20 minutes in 1% paraformalde-
hyde (BDH, Poole, United Kingdom), and rinsed in PBS. Slides were blocked
with 2% normal mouse serum (Dako Cytomation, Glostrup, Denmark), fol-
lowed by incubation for at least 1 hour with primary antibodies specific for
CD4 (eBioscience, San Diego, Calif), CD8 (BD Biosciences, San Jose, Calif),
or MHC I (BioLegend, San Diego, Calif). After washing, slides were incu-
bated for 30 to 45 minutes with alkaline phosphatase–conjugated anti-rat
secondary antibody (Dako). Naphthol red was used as a substrate (Sigma,
St Louis, Mo), and hematoxylin (Merck, Darmstadt, Germany) was used for
counterstaining.Assessment of diabetes
Blood glucose concentrations were analyzed from a drop of blood by using
a Glucometer Elite (Bayer, Tarrytown, NY). When animals showed blood
glucose levels of greater than 14 mmol/L on 2 consecutive days, they were
considered diabetic.Fluorescence-activated cell sorting analysis
Tetramer production and fluorescence-activated cell sorting (FACS)
analysis were performed as described previously.39 Briefly, splenocytes or
peripheral blood lymphocytes were stained with phycoerythrin-labeled
GP33 MHC class I tetramers (GP33/H-2Db) for 15 minutes at 378C, followed
by staining with anti-CD8 (BD Biosciences) for 30 minutes at 48C. For de-
termination of LCMV-specific CD4 T cells, lymphocytes were stained with
anti-CD4 and anti-Thy1.1 (CD90.1, BD Biosciences). For determination of
their activation status, lymphocytes were stained with anti-CD25, anti-
CD69, anti-GITR, anti-CD62 ligand, anti-CD44, and anti–IL-7 receptor a
(BD Biosciences) for 30 minutes at 48C. Cells were fixed with 1% formalin
and permeabilized with saponin. Cells were stained for intracellular IFN-g,
FIG 1. Absence of WASP enhances virus-induced immunopathology. Virus-induced immunopathology
was analyzed as serum alanine aminotransferase (ALT) activity (A) and bilirubin levels (B) after LCMV infec-
tion. Viral clearance was assessed by measuring viral titers in the liver (C). The presence of CD41 and CD81
T cells in the liver was analyzed bymeans of immunohistochemistry (D). Data in Fig 1,A and B, are means6
SEMs and peaks (Fig 1,A: C57BL/6mice, n5 6-12;WAS KOmice, n5 8-10) or areas under the curve (Fig 1, B:
C57BL/6 mice, n 5 5-9; WAS KO mice, n 5 5-6) compared by using the Student t test. Symbols in Fig 1, C,
represent individual mice, and images in Fig 1, D, are representative of data shown in Fig 1, C.
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Burlingame, Calif). IFN-a production by DCs was assessed by means of in-
tracellular FACS after culture of bone marrow cells for 10 days with Flt3L
(100 ng/mL; Peprotech, Rocky Hills, NJ). For identification of DCs,
CD11c (BD Biosciences) was used, and CD8a, CD11b, and B220 or
pDCA1 (BD Biosciences) were used to distinguish between CD81 cells,
conventional dendritic cells (cDCs), and plasmacytoid dendritic
cells (pDCs), respectively. Cells were analyzed with a FACSCalibur or
FACSCanto II (BD Biosciences).
T-cell priming
DCs were cultured from bone marrow cells in the presence of GM-CSF
(20 ng/mL; Invitrogen, Carlsbad, Calif) for 7 days and pulsed overnight with
ovalbumin (100 mg/mL, Sigma) and LPS (100 ng/mL, Sigma). DCs (23 106)
were injected subcutaneously into the tail base of wild-type C57BL/6 mice,
and spleens and draining lymph nodes (inguinal) were harvested at the indi-
cated time points. Single-cell suspensions of lymph nodes and spleens were
cocultured with SIINFEKL peptide (2 mmol/L; Proimmune, Oxford, United
Kingdom) and RMA-S cells (kindly provided by Dr Anne-Marie McNicol)
in the presence of brefeldin A (5 mg/mL, Sigma). The RMA-S cells were
incubated overnight at 268C before the experiment to establish expression
of empty MHC class I molecules on the cell surface, which will present the
SIINFEKL peptide during culture with lymph node or spleen cells. After4 hours, the cells were stained with fluorescein isothiocyanate (FITC)–conju-
gated CD3 and peridinin-chlorophyll-protein complex–conjugated CD8 and
then permeabilized (BD Perm/Wash, BD PharMingen) and stained with
phycoerythrin-conjugated IFN-g (eBioscience). The cells were analyzed on
a Cyan flow cytometer.IFN-a ELISA
Mice were infected with LCMV or VSV or injected with polyinosine-
polycytidylic acid (Poly[I:C]) and blood obtained at the indicated time points.
Serum IFN-a levels were determined by using ELISA, according to the
manufacturers’ specifications (Research Diagnostics RDI, Flanders, NJ).Cytotoxicity assay
EL4 target cells were loaded with 51Cr and pulsed with or without GP33 or
NP396. Splenocytes of immunized mice were incubated directly ex vivo
(primary) or after restimulation with GP33 or NP396 for 5 days (secondary)
with the target cells. Supernatants were assessed after 8 hours. For killing of
allogeneic BALB/c splenocytes, a Cytotox 96 nonradioactive kit (Promega,
Madison, Wis) was used according to the instructions provided. Ficoll-
purified T cells were plated at the effector/target ratios shown by using 104
BALB/c splenocytes (target cells). Lactate dehydrogenase release was
assayed after 4 hours of incubation at 378C.
FIG 2. Reduced incidence of virus-induced diabetes. C57BL/6 and WAS KO bone marrow was transferred
into irradiated RIP-GP mice, and after 50 days, mice were infected with LCMV. Insulitis was determined by
means of immunohistochemistry (A) and incidence of diabetes analyzed (B; n 5 4). Transgenic WAS KO/
RIP-GP mice were made by crossing RIP-GP mice with WAS KO mice. Mice were infected with LCMV,
and the incidence of diabetes was analyzed (C; n 5 8).
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Statistical analysis
Data are expressed as means6 SEMs. When comparing data expressed as
curves, linear regression was used. When curves did not follow a linear
pattern, the area under the curve or peak values were determined and
compared by using the Student t test. When comparing 2 groups, the Student
t test was used. Survival data were analyzed by using the log rank test. All sta-
tistical tests were performed with Prism 5 software (GraphPad Software, La
Jolla, Calif). P values of less than .05 were considered statistically significant.
RESULTS
Reduced viral clearance in WAS KO mice
To investigate the ability of WAS KO mice to mount a
protective immune response against viral infection and to inves-
tigate immunopathology, we challenged mice with LCMV (WE
strain). Serum alanine aminotransferase and total bilirubin levels
were used as a direct measurement of virus-induced hepatic
immunopathology.33 WAS KO mice showed a similar, although
slightly earlier, alanine aminotransferase response but exhibited
increased bilirubin levels after viral challenge (Fig 1, A and B).
Furthermore, WAS KO mice showed persistence of viral replica-
tion and a hepatic T-cell infiltrate 15 days after infection, whereas
by that time, wild-type C57BL/6 animals had cleared viral infec-
tion and showed no sign of T-cell infiltration (Fig 1, C and D).
These finding indicate that WAS KO mice are compromised in
their ability to clear LCMV, despite the presence of an inflamma-
tory T-cell infiltrate.Defective induction of CD81 T-cell responses
Weused theRIP-GPmodel of autoimmune diabetes to study the
induction of an effective antiviral CD81 T-cell response in vivo.
Thesemice express the LCMVglycoprotein under regulatorycon-
trol of the rat insulin promoter, resulting in b cell–restricted
expression. On infection with LCMV, healthy mice mount an
anti-LCMV immune response, which is dominated by the genera-
tion of glycoprotein-specific cytotoxic CD81 T cells that not only
clear the virus but also destroy the b cells that express the LCMV
glycoprotein, subsequently inducing development of diabetes.40
We created bone marrow chimeras by transferring WAS KO or
wild-type C57BL/6 bone marrow into lethally irradiated RIP-
GP mice and challenged the mice after a further 50 days with
LCMV. Despite the development of insulitis (Fig 2, A), character-
ized by infiltration ofCD41 andCD81Tcells into theb-cell–con-
taining islets of Langerhans, and generalized upregulated
expression of MHC class I as a result of inflammatory conditions,
mice reconstituted withWASKO bone marrow did not have overt
diabetes (Fig 2, B). Similarly, when RIP-GP mice were crossed
with WAS KO mice, the incidence of overt diabetes after
LCMV challenge was significantly reduced compared with that
seen in RIP-GP single transgenic animals (Fig 2, C), although
not to the extent seen in bone marrow chimeric mice, which is
probably due to the additional immunosuppressive effects of irra-
diation and bone marrow transplantation.
To analyze the CD81 response in vivo in more detail, we
infected wild-type C57BL/6 or WAS KO mice with LCMV and
analyzed the virus-specific CD81 T-cell response. Six days after
infection, the total number of CD81 T cells and LCMV-specific,
FIG 3. Impaired CD81 T-cell response in patients with WASP deficiency. The virus-specific CD81 T-cell
response was analyzed after LCMV infection as the total number of CD81 T cells (left panel) or the number
of LCMV-specific, GP33-tetramer–positive CD81 T cells (right panel) in the spleen (A), liver (B), and blood (C).
IL-7R expression was determined on virus-specific CD81 T cells (D). IFN-g expression was analyzed by using
FACS after restimulation of in vivo–primed (day 6) virus-specific T cells (E). Swelling of the footpad after
LCMV infection was analyzed over time (F). Cytotoxicity of CD81 T cells was determined in virus-specific
(F) and allogeneic (G) settings. Data are shown as means 6 SEMs in Fig 3, A to C, and represent 4 to 8
mice (C57BL/6 mice: day 6, n 5 5-6; day 12, n 5 7-8; day 20, n 5 4-5; WAS KO mice: day 6, n 5 6; day 12,
n 5 6; day 20, n 5 4); Fig 3, D, n 5 3, representative of at least 2 independent experiments; Fig 3, E, n 5 5
to 6; Fig 3, F, n 5 6 to 8; Fig 3, G, n5 6; and Fig 3, H, is a representative experiment of 2 independent exper-
iments with a total of n 5 4.
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blood was similar between C57BL/6 and WAS KO mice (Fig 3,
A-C). However, on days 12 and 20 after infection, the numbers
of total and virus-specific CD81 T cells recovered from blood
was markedly reduced in WAS KO mice (Fig 3, C), whereas at
that time, LCMV had been eliminated in C57BL/6 mice (Fig 1,
C). WAS KO mice also mounted CD81 T-cell responses specific
for the immunodominant epitope of the LCMV nucleoprotein
(NP396), but although reduced compared with values seen in
C57BL/6 mice, this did not reach statistical significance (see
Fig E1 in this article’s Online Repository at www.jacionline.
org). A typical CD81 T-cell response will peak around day 8 after
infection, after which only a small subset of CD81 T cells will
survive and develop into memory T cells. This subset can be iden-
tified by IL-7 receptor (IL-7R) expression.39,41,42We analyzed the expression of IL-7R on GP33 and NP396
tetramer–positive cells at day 8 after infection and found fewer
IL-7R1 virus–specific CD81 T cells in WAS KOmice (Fig 3,D).
We then analyzed the function of virus-specific CD81 T cells in
more detail and found that splenic WASP-deficient CD81
T cells isolated at day 6 after infection were impaired in their
ability to produce intracellular IFN-g after restimulation in vitro
with GP33 and NP396 peptides (Fig 3, E). Next, we injected
LCMVin the footpads of mice because footpad swelling is depen-
dent on viral titer, CD81 T-cell infiltration, and CD81 T-cell
cytotoxicity43 and found thatWASKO animals exhibited a signif-
icantly diminished response (Fig 3, F). Finally, we tested the
ability of WAS KO CD81 T cells to specifically lyse target cells
in vitro. T cells were collected at day 6 after infection when
antigen-specific cell numbers were equivalent between WAS
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cytotoxicity to cells presenting the virus-specific GP33 and
NP396 epitopes (Fig 3, G). To investigate whether this was due
to intrinsic dysfunction of WAS KO CD81 T cells, we analyzed
the ability of WAS KO CD81 T cells to lyse allogeneic BALB/c
splenocytes and observed that WAS KO CD81 T cells also
showed reduced cytotoxicity in this nonviral setting (Fig 3, H).
Overall, these findings suggest an intrinsic cytotoxic dysfunc-
tion ofWASKOCD81T cells but also amore complex disruption
to priming and long-term survival after antigen challenge.Impaired priming of CD81 T cells
Because T cells require antigen-specific stimulation by DCs for
optimal priming, we investigated the contribution of defective
DC-mediated T-cell priming to abnormal CD81 T-cell responses.
We adoptively transferred bone marrow–derived WAS KO DCs
pulsed with ovalbumin intowild-type C57BL/6 recipients and an-
alyzed the antigen-specific IFN-g response. Both in spleens and
draining lymph nodes, we observed reduced numbers of IFN-
g–producing wild-type CD81 T cells in response to secondary
challenge with ovalbumin (Fig 4, A and B), suggesting thatdefective priming by DCs at least in part contributes to defective
function of WAS KO CD81 T cells. Priming of virus-specific
CD81 T cells is also strongly dependent on IFN-Is, acting either
directly on the CD81 T cells or by maturing DCs necessary for
antiviral T-cell immunity.44,45 Accordingly, we analyzed the
IFN-I response in WAS KO mice after infection with LCMV. In-
duction of serum IFN-a was significantly abrogated in WAS KO
mice in response to LCMV infection (Fig 5, A). Similarly, when
we infected mice with VSVor administered the nonviral, nonrep-
licating, IFN-I stimulator Toll-like receptor (TLR) 3/RIG-I ligand
Poly(I:C) in vivo,WASKOmice exhibited amarkedly diminished
IFN-a response (Fig 5,B andC). These findings indicate a general
reduction in stimulated IFN-I production in vivo in the absence of
WASP expression.Decreased expression of IFN-I by DCs
To investigate which cells were responsible for the defective
production of IFN-Is, we made use of the IFN-b reporter–knock-
in mouse, in which yellow fluorescent protein (YFP) expression is
bicistronically linked to expression of IFN-b of the endogenous
ifnb locus, so that IFN-b–producing cells can easily be identified
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CD11c1CD8a1CD11b2B2202 cells, CD11c1CD8a2CD11b1B2202 cells, and CD11c1CD11b2B2201 cells, re-
spectively. IFN-a expression was determined by using intracellular FACS of in vitro–cultured DC subsets
(E). Symbols in Fig 6, B, represent individual mice, and the line is the mean. Data in Fig 6, C to E, are ex-
pressed as means 6 SEMs of (Fig 6, C and D) n 5 4. Fig 6, E, LPS and CpG, n 5 7; Poly(I:C), n 5 4.
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crossed with WAS KO mice and challenged with Poly(I:C). As
expected, we found that in the absence of WASP, IFN-b/YFP
expression was reduced in splenocytes and that this was restricted
to CD11c1 cells (Fig 6, A and B). To verify that this was not
caused by an overall reduction in the number of DCs in WAS
KO mice, we analyzed the proportion of conventional migratory
(cDCs; CD11c1CD11b1CD8a2B2202), conventional CD8a1(CD11c1CD11b2CD8a1B2202), and plasmacytoid (pDCs;
CD11c1CD11b2B2201 or CD11c1mPDCA11) DC subsets.
As expected from previous reports,14,47 we did not observe signif-
icant differences between distinct subsets in spleens or lymph
nodes in C57BL/6 or WAS KO mice (Fig 6, C and D, and see
Fig E2, A, in this article’s Online Repository at www.jacionline.
org). Total splenocyte and lymph node cell numbers in WAS
KO and C57BL/6 mice were comparable, as were absolute cell
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the impaired production of IFN-I observed in vivo reflected an in-
trinsic deficiency of DCs in the absence ofWASP. Both pDCs and
cDCs showed a reduced IFN-a response when stimulated with
Poly(I:C), CpG, and LPS in vitro (Fig 6, E). Similarly, when we
used ex vivo–isolated splenic CD11c1 cells, a similar deficiency
in IFN-a production in response to Poly(I:C), LPS, and CpG was
observed (see Fig E2, F). These findings show that WAS KODCs
are intrinsically compromised in their ability to secrete IFN-I.DISCUSSION
Patients with WAS have recurrent viral infections,3,4 but rela-
tively little is known about the mechanistic role of WASP in anti-
viral immunity.We found thatWASKOmice did not clear LCMV
infection and had exaggerated immunopathology. One possibility
is that there was reduced homing of inflammatory cells to the sites
of infection.9 However, we observed a persistent infiltration of
CD41 and CD81 T cells in the liver after viral infection, suggest-
ing that reduced viral clearance is not primarily the result of
defective CD81 T-cell migration. In chimeric or transgenic
RIP-GP/WAS KO mice, we observed T-cell infiltration around
the islets of Langerhans, which is typically associated with the
onset of diabetes. Both in antigen-specific and allogeneic settings,
we observed reduced cytotoxic function of WAS KO CD81
T cells. Overall, these findings indicate that there are intrinsic
defects of cytotoxicity in WAS KO CD81 T cells and that they
play a significant role in the control of viral infection in vivo.
These findings are also in line with a recent report showing that
cytotoxicity is reduced in human WASP-deficient CD81 T cells
and that WASP is required for delivery and polarization of the
lytic granules toward the center of the immunologic synapse.29
Similar to cytotoxic T cells, impaired lytic activity of natural
killer (NK) cells in patients with WAS has also been reported.48
In addition, defective NK cell function can result from impaired
DC priming,49 but the role of NK cells in LCMV-mediated immu-
nity is expected to be limited because depletion of NK cells im-
proves CD81 T-cell immunity.50 Impaired immunologic
synapse formation is likely to contribute to defective CD81
T-cell function.14 Dependence on WASP for DC-mediated prim-
ing has previously also been demonstrated for CD41 T cells and
NK cells, in whichWASP was shown to be required for formation
of an activating immunologic synapse.6,13,49 Perhaps most strik-
ingly, although at early time points the CD81 T-cell response to
LCMVappears relatively normal, it is poorly sustained compared
with that observed in normal micewith fewer IL-7R1 cells, mark-
ing a reduction in survival and memory CD81 T-cell develop-
ment. It therefore appears that WASP deficiency not only
intrinsically impairs the function of CD81 T cells, as shown by
reduced cytotoxicity and IFN-g production, but also results in
abrogated survival or expansion. This might help explain the pro-
gressive immunodeficiency observed in patients with WAS as a
consequence of accelerated exhaustion.
IFN-Is are crucial for the control of LCMV replication. In
complete absence of IFN-Is, no detectable virus-specific CD81
T-cell response is mounted.36 Ligation of host pattern-
recognition receptors, such as the cytoplasmic helicase RIG-I
family and TLR3, TLR7, and TLR9, triggers activation of the
transcription factor interferon regulatory factor 7, which translo-
cates to the nucleus, where it promotes IFN-I production.37,51
IFN-Is are normally induced at early time points after viralinfection and are therefore critical for control of replication and
establishment of a definitive immunologic clearance. WAS KO
animals demonstrated reduced IFN-I production by DCs after
LCMVand VSV infections, as well as after nonviral stimulation
of TLR3 and TLR9. Normal pDCs are known for their ability to
quickly produce large amounts of IFN-a in response to viral infec-
tion or TLR9 ligation. Depletion of pDCs abrogates virus induced
IFN-a production and exacerbates virus-induced immunopathol-
ogy, including diminished CD81 T-cell responses.52,53 Normally,
a rapid expansion of splenic IFN-I–producing pDCs can be
observed in response to LCMV infection.54 There were no differ-
ences in the frequency of pDCs in WAS KO mice in the steady
state, but on stimulation with viral or TLR ligands, WAS KO
pDCs showed significantly reduced ability to produce IFN-Is
both in vitro and in vivo. The expansion of virus-specific CD81
T cells has been shown to be strongly dependent on IFN-Is, acting
directly on CD81 T cells to promote survival during antigen-
driven proliferation and subsequent establishment of mem-
ory.34,43,44,55 Furthermore, IFN-Is play a key role in enhancing
the maturation and activation of DCs.45 It therefore seems likely
that a reduced IFN-I response in WAS KO mice contributes to
theweakened antiviral CD81T-cell response by directly affecting
CD81 T-cell function, influencing the activation of DCs, or their
combination. pDC activation by inducible natural killer T cells
has been reported to play an important role in control of LCMV
infection through stimulation of IFN-I production.56 Patients
with WAS and WAS KO mice have impaired homeostasis and
function of iNKT cells, and therefore it is interesting to speculate
that there might be a mechanistic link.57,58 Further studies will be
required to determine whether defective iNKT cell function
affects pDC function in WAS KO model systems.
In conclusion, we have shown thatWASP is required tomount a
protective antiviral immune response in an in vivo model of
persistence-prone LCMV infection. In the absence of WASP, a
markedly diminished CD81 T-cell response is induced, which
most likely is the combination of intrinsic dysfunction of
WASP-deficient CD81 T cells and impaired priming and mainte-
nance by IFN-I–producing DCs. This also raises the possibility
that IFN-I therapy might be useful for refractory or chronic viral
infections in patients with WAS.
We thank Alisha Elford, Konstanze Sch€attel, and Patricia Spieker for
technical support; Dr Siobhan Burns for critical reading of themanuscript; and
the National Institutes of Health’s tetramer facility for providing tetramers.
Key messages
d WASP-deficient mice show reduced viral clearance and
enhanced virus-induced immunopathology.
d Priming and effector function of CD81 T cells is impaired
in patients with WASP deficiency.
d IFN-I production by DCs is reduced in the absence of
WASP.
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FIG E1. Analysis of the T-cell response for the immunodominant epitope of
LCMV nucleoprotein. The virus-specific CD81 T-cell response for the immu-
nodominant epitope of the LCMV nucleoprotein was analyzed 12 days after
LCMV infection. Data are shown as means 6 SEMs (n 5 3).
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FIG E2. Total number of leukocytes in lymphoid tissue. The number of splenic CD11c1mPDCA11 pDCs (A)
and the total number of leukocytes was determined in spleens (B) and lymph nodes (C). DC subsets were
quantified in spleens (D) and lymph nodes (E). IFN-a expression was determined by means of intracellular
flow cytometry after stimulation of ex vivo–isolated DC subsets (F). Symbols in Fig E2, A to C, represent in-
dividual mice, and the line indicates the mean. Data in Fig E2, D to F, are expressed as means 6 SEMs of
n 5 4. Fig E2, F, LPS and CpG, n 5 7; Poly(I:C), n 5 4.
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